Recent News

• 08.06.2026 - Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
• 08.06.2026 - Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
• 06.30.2026 - Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
• 06.26.2026 - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
• 06.25.2026 - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
• 06.13.2026 - Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
• 06.11.2026 - 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
• 06.08.2026 - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
• 05.07.2026 - Ascendis Pharma Reports First Quarter 2026 Financial Results
• 05.06.2026 - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Recent Filings

• 08.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.17.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities